Vaccine Platform Technology

Abera’s highly efficient vaccine platform technology, BERA, enables display of antigens at the surface of OMVs.

The BERA Vaccine Platform – A Next-Generation Approach to Vaccine Development

The BERA vaccine platform is an innovative and highly adaptable vaccine technology developed by Abera Bioscience. Built on over 30 years of research, it leverages Outer Membrane Vesicles (OMVs) to create safe, effective, and scalable vaccines. With its plug-and-play design, the BERA platform enables rapid development of vaccines for infectious diseases, including influenza, COVID-19, and other emerging threats.

Do you find our technology interesting and would you like to discuss a collaboration? Don’t hesitate to contact us.

BERA Vaccine Platform Technology
hexa-03

Outer Membrane Vesicles (OMVs) – A Powerful Vaccine Delivery System

The BERA vaccine platform utilizes genetically engineered OMVs—nanosized spherical vesicles that naturally bud from bacterial membranes. These OMVs act as powerful immune stimulators, triggering both systemic and mucosal immunity. Unlike traditional vaccine vectors, OMVs are non-replicating and highly safe while maintaining strong adjuvant properties.

Plug-and-Play Vaccine development

One of the greatest advantages of the BERA vaccine technology is its modular design. By decorating OMVs with different disease-specific antigens, Abera Bioscience can quickly design and produce new vaccines. This enables:

  • Rapid response to emerging infectious diseases
  • Cost-effective vaccine production
  • Customizable antigen selection for different diseases

Mucosal Immunization – Blocking Infection at the Source

Unlike many traditional vaccines, the BERA vaccine platform enable nasal delivery, triggering a strong immune response at mucosal surfaces—the primary entry point for many bacteria and viruses. By preventing bacterial colonization and viral replication in the nose and lungs, BERA-based vaccines have the potential to halt transmission and stop outbreaks before they spread.

Scalable and Cost-Effective Production

The BERA platform enables large-scale vaccine manufacturing at a lower cost compared to traditional vaccine production. Thanks to its efficient OMV-based system, vaccine candidates can be developed, tested, and produced within an few weeks, ensuring a rapid response to pandemic threats.

Learn More about the BERA Vaccine Platform

At Abera Bioscience, we are committed to revolutionizing vaccine technology with the BERA vaccine platform. If you’re interested in collaborating or learning more, contact us at info@aberabio.com.

Visit our Pipeline page for more details on our development projects: www.aberabio.com/projects